Acadia Pharmaceuticals
ACAD
273 hedge funds and large institutions have $6.41B invested in Acadia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 71 funds opening new positions, 97 increasing their positions, 78 reducing their positions, and 26 closing their positions.
173% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 26
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 78
21% more capital invested
Capital invested by funds: $5.28B → $6.41B (+$1.13B)
18% more funds holding
Funds holding: 231 → 273 (+42)
2% more call options, than puts
Call options by funds: $86.9M | Put options by funds: $85M
0.11% less ownership
Funds ownership: 97.32% → 97.22% (-0.11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$133M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
+$33.7M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$32.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$30.9M |
| 5 |
BlackRock
New York
|
+$30.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$113M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$47.9M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$40.9M |
| 5 |
D.E. Shaw & Co
New York
|
-$38.9M |
ACAD Hedge Fund Activity: Q4 2019 in Review
273 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2019, worth a combined $6.41B — up 21% from $5.28B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new ACAD positions and 26 closed out — a net gain of 45 holders — while 97 added to existing stakes and 78 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $133M. The largest seller was Invesco, cutting an estimated $113M.
- 273 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2019, up from 231 in Q3 2019.
- Funds reported $6.41B of Acadia Pharmaceuticals stock for Q4 2019, up 21% quarter-over-quarter.
- 71 funds opened new Acadia Pharmaceuticals positions in Q4 2019 and 26 closed out, a net change of +45 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2019 was T. Rowe Price Associates, an estimated $133M added.
- The largest Acadia Pharmaceuticals seller in Q4 2019 was Invesco, an estimated $113M sold.
Based on aggregated 13F filings for Q4 2019.